Antengene Corp

Antengene Corp PEG

The PEG Ratio (Price/Earnings-to-Growth) of Antengene Corp (6996.HK) as of Nov 3, 2026 is -0.39. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was -0.11 — a change of 266.49% (lower).

PEG

-0.39

YoY

266.49%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Antengene Corp is 2025 -0.39 . PEG Ratio (Price/Earnings-to-Growth) of Antengene Corp was 2024 -0.11 . It decreases by 266.49% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Antengene Corp Stock analysis

What does Antengene Corp do? Antengene Corp. Ltd. generates revenue through the development and commercialization of biopharmaceutical products, primarily targeting cancer treatments. The company focuses on ATG-010 (selinexor), which is used for relapsed/refractory multiple myeloma, diffuse large B-cell lymphoma, and non-small cell lung cancer, and ATG-008 (onatasertib), indicated for hepatocellular carcinoma and non-small cell lung cancer. These products are developed for the Asia-Pacific market, where the company conducts its main operations. The firm's revenue streams are derived from the clinical-stage development and eventual commercialization of these therapies, targeting healthcare providers and patients in the region. The company operates as a clinical-stage biopharmaceutical entity, emphasizing discovery, development, manufacturing, and commercialization of innovative cancer treatments. Its primary products, ATG-010 and ATG-008, are designed to address specific oncology indications, with a focus on relapsed or refractory conditions. The Asia-Pacific market serves as the core geographic segment for its business, where it aims to establish a strong presence through its pipeline of biotech products. Revenue is anticipated once these therapies advance through clinical trials and receive regulatory approvals for commercial use. Antengene Corp. Ltd. targets healthcare systems and oncology specialists in the Asia-Pacific region for its biopharmaceutical products. The company’s products are positioned for treatment of complex cancer types, with ATG-010 addressing multiple myeloma and lymphoma, and ATG-008 targeting liver and lung cancers. As a clinical-stage company, its current focus is on advancing these therapies through development stages, with commercialization expected to drive future revenue. The Asia-Pacific market remains central to its business strategy, where it leverages its regional presence to build partnerships and market access. Antengene Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Antengene Corp stock

PEG Ratio (Price/Earnings-to-Growth) of Antengene Corp is -0.39 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of Antengene Corp changed from -0.11 to -0.39, representing a 266.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Antengene Corp since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Antengene Corp with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Antengene Corp

All Key Metrics — Antengene Corp